Company intelligence / Profile preview
OssiFi Therapeutics
Kansas City / Overland Park, Kansas, United Statesossifi.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
OssiFi develops first-in-class bone-building small molecule inhibitors targeting sclerostin to provide safer and more effective therapies for bone-related conditions. The company aims to outperform current antiresorptive treatments by directly increasing bone density. It has filed multiple patents in the area of rare diseases and skeletal disorders but no published clinical trial results yet.
- Therapeutic areas
- OtherEndocrinologyRare DiseasesNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Binational Industrial Research and Development Foundation (grant funding partner)
Beyond the preview
Go deeper on OssiFi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OssiFi Therapeutics.